Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336491 | 1.00 | TLR8 (0.50) | TLR8GPR84TLR7KCNH2GPBAR1 | |
| SCHEMBL27991341 | 0.98 | TLR8 (0.49) | TLR8GPR84TLR7KCNH2TRPV1 | |
| SCHEMBL7069013 | 0.95 | TLR8 (0.49) | TLR8TLR7TRPV1 | |
| SCHEMBL28146413 | 0.90 | GPBAR1 (0.49) | TLR8KCNH2GPBAR1 | |
| SCHEMBL9971271 | 0.87 | KDM4E (0.44) | TLR8TRPV1 | |
| SCHEMBL8501798 | 0.84 | KDM4E (0.37) | TLR8 | |
| SCHEMBL27951625 | 0.84 | TLR8 (0.39) | TLR8 | |
| SCHEMBL28605200 | 0.83 | HRH1 (0.42) | TLR8 | |
| SCHEMBL6001793 | 0.81 | JAK2 (0.38) | TLR7 | |
| SCHEMBL3021084 | 0.81 | KDM4E (0.35) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103113311-A | 2-aryl quinazoline or 2-heterocyclic aryl quinazoline derivative and preparation method thereof | UNIV NANJING POSTS & TELECOMM | 2013-05-22 | — | — | CN | claimed |
| CN-110446707-B | Pharmaceutical preparation | 默克专利股份公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4286007-A2 | PHARMACEUTICAL FORMULATION | Merck Patent GmbH (DE) | 2023-12-06 | — | — | EP | disclosed |
| EP-3601277-B1 | PHARMACEUTICAL FORMULATION | MERCK PATENT GMBH (DE) | 2023-10-11 | — | — | EP | disclosed |
| EP-3601265-B1 | SOLID FORM OF (S)-[2-CHLORO-4-FLUORO-5-(7-MORPHOLIN-4-YLQUINAZOLIN-4-YL)PHENYL]-(6-METHOXY-PYRIDAZIN-3-YL)METHANOL | MERCK PATENT GMBH (DE) | 2023-06-21 | — | — | EP | disclosed |
| CN-110446706-B | Crystalline forms of (S) - [ 2-chloro-4-fluoro-5- (7-morpholin-4-ylquinazolin-4-yl) phenyl ] - (6-methoxy-pyridazin-3-yl) methanol | 默克专利股份公司 | 2023-05-16 | — | — | CN | disclosed |
| US-20230119567-A1 | PHARMACEUTICAL FORMULATION | MERCK PATENT GMBH (DE) | 2023-04-20 | — | — | US | disclosed |
| CN-110446705-B | Solid forms of (S) - [ 2-chloro-4-fluoro-5- (7-morpholin-4-ylquinazolin-4-yl) phenyl ] - (6-methoxy-pyridazin-3-yl) methanol | 默克专利股份公司 | 2023-04-14 | — | — | CN | disclosed |
| US-11559490-B2 | Pharmaceutical formulation | MERCK PATENT GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-3601271-B1 | CRYSTALLINE FORM OF (S)-[2-CHLORO-4-FLUORO-5-(7-MORPHOLIN-4-YLQUINAZOLIN-4-YL)PHENYL]-(6-METHOXY-PYRIDAZIN-3-YL)-METHANOL | MERCK PATENT GMBH (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-0871448-A4 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE POULENC RORER PHARMA (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999032460-A1 | SUBSTITUTED 2-ARYL-4-AMINO-CHINAZOLINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-01 | — | — | WO | disclosed |
| EP-0871448-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5710158-A | INHIBITORS OF PROTEIN TYROSINE KINASE AND EPIDERMAL GROWTH FACTOR | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0537600-B1 | An improved process for the preparation of 4-haloquinazolines | DOWELANCO (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1995015758-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-06-15 | — | — | WO | disclosed |
| US-4306065-A | HYPOTENSIVE | A. H. ROBINS COMPANY, INCORPORATED (US) | 1981-12-15 | — | — | US | disclosed |
| US-3998951-A | Substituted 2-arylquinazolines as fungicides | FMC CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
| US-3998951-A | Substituted 2-arylquinazolines as fungicides | FMC CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
| US-3998951-A | Substituted 2-arylquinazolines as fungicides | FMC CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119567-A1 | PHARMACEUTICAL FORMULATION | CYP3A7, RAB8A, RAB5C | TLR8 602/4885GPR84 4666/4885TLR7 178/4885 |
| US-11559490-B2 | Pharmaceutical formulation | CYP3A7, RAB8A, RAB5C | TLR8 602/4885GPR84 4666/4885TLR7 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.